Ataluren

BNF:
Not listed
Status:
Red
Decision Date:
August 2016
 

Comments

RED:

  • NICE HST3: for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene.  (Decision date - August 2016).
  • HST22 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. (Decision date - March 2023)

NHS England drug - to be used in line with NHSE commissioning intentions.

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app